In contrast to well-characterized Akt posttranslational modifications identified in the past19, our knowledge about how non-enzymatic Akt binding proteins modulate Akt activity in cancer is limited, and whether Akt PPIs can be exploited for cancer therapy remains to be determined. The gene discussed is AKT1; the disease is cancer.